| 常用名 | 艾拉莫德 | CAS号 | 123663-49-0 |
|---|---|---|---|
| 价格 | ¥需询单/1kg | 纯度 | 98.0% |
| 备货期 | 1天 | 库存 | 现货 |
| 产品详情(用途,包装等)
英文别名 T 614 Ailamode Iguratimod IGURATIMOD IguratiMod (T 614) N-[7-methanesulfonamido-4-oxo-6-(phenoxy)chromen-3-yl]formamide N-(7-(MethylsulfonaMido)-4-oxo-6-phenoxy-4H-chroMen-3-yl)forMaMide N-[3-(formylamino)-4-oxo-6-phenoxy-4H-chromen-7-yl]methanesulfonamide 3-(Formylamino)-7-(methylsulfonylamino)-6-phenoxy-4H-1-benzopyran-4-one N-[3-(Formylamino)-4-oxo-6-phenoxy-4H-1-benzopyran-7-yl]methanesulfonamide CAS 123663-49-0 EINECS 808-127-0 化学式 C17H14N2O6S 分子量 374.37 InChI InChI=1/C17H14N2O6S/c1-26(22,23)19-13-8-15-12(17(21)14(9-24-15)18-10-20)7-16(13)25-11-5-3-2-4-6-11/h2-10,19H,1H3,(H,18,20) 密度 1.52±0.1 g/cm3(Predicted)
熔点 238.0 to 242.0 °C 沸点 580.6±60.0 °C(Predicted) 闪点 304.9°C 蒸汽压 1.8E-13mmHg at 25°C 溶解度 DMSO (Slightly) 折射率 1.673 酸度系数 5.58±0.20(Predicted) 存储条件 under inert gas (nitrogen or Argon) at 2-8°C 外观 Solid 颜色 White to Off-White 体外研究 Iguratimod (T-614) is an antirheumatic agent, acts as an inhibitor of COX-2, with an IC 50 of 20 μM (7.7 μg/mL), but shows no effect on COX-1. Iguratimod (0.1, 1, 10 μg/mL) inhibits bradykinin-stimulated PGE2 release from fibroblasts. Iguratimod suppresses the COX activity from bradykinin stimulated fibroblasts in a concentration-dependent manner, with an IC 50 of 48 μg/mL. Iguratimod (10 and 30 μg/mL) also dose-dependently inhibits COX-2 mRNA levels. In addition, Iguratimod potently inhibits macrophage migration inhibitory factor (MIF) with an IC 50 of 6.81 μM. Iguratimod is synergetic with glucocorticoids in vitro. 体内研究 Iguratimod (5 or 20 mg/kg) shows analgesic effect, significantly improves the pain withdrawal threshold of the left hind paw in dose-dependent manner in rats. Iguratimod (5 or 20 mg/kg) reduces the elevation of pERK1/2 and c-Fos in the spinal cord induced by cancer cell inoculation. Iguratimod also dose-dependently decreases the IL-6 levels in rats. In Iguratimod-treated rats, the activity of osteoclasts is weaker than the control group. Iguratimod (20 mg/kg i.p.) shows significantly increased survival in BALB/c mice that are vulnerable to endotoxemia, and attenuates TNFα release measured in serum isolated 90 min post-LPS administration in wild-type C57BL/6 mice. 更多
|